🇪🇺 Panretin in European Union

EMA authorised Panretin on 11 October 2000

Marketing authorisation

EMA — authorised 11 October 2000

  • Application: EMEA/H/C/000279
  • Marketing authorisation holder: Eisai GmbH
  • Local brand name: Panretin
  • Indication: Panretin gel is indicated for the topical treatment of cutaneous lesions in patients with acquired-immune-deficiency-syndrome (AIDS)-related Kaposi's sarcoma (KS) when: lesions are not ulcerated or lymphoedematous, and; treatment of visceral KS is not required, and; lesions are not responding to systemic antiretroviral therapy, and; radiotherapy or chemotherapy are not appropriate.
  • Status: withdrawn

Read official source →

Panretin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is Panretin approved in European Union?

Yes. EMA authorised it on 11 October 2000.

Who is the marketing authorisation holder for Panretin in European Union?

Eisai GmbH holds the EU marketing authorisation.